<+>=<+>KOLA Newslist<+>=<+>
 

From: Donna Ennis <Metis111@aol.com>
Date: Tue, 22 Feb 2000 11:49:40 EST
Subject: Fwd: Senator Daschles reply info on Pneumona Coccia Vaccine

This is a response I got from Tom Daschle, Senator for South Dakota.  Seems
to me he is one of the larger of the hipocrits on Capitol Hill.  This is the
biggest cop out I have ever seen in print.  That man has no idea what state I
live in or anything about me.  What does it matter where I live, this issue
is of the utmost importance and needs the immediate attention of ALL people,
not just indian people.  I have also sent this news release to the NAACP, I
bet they get results.

Please write to Senator Daschle and push him on this outrage, he is one of
the Senate Minority Leaders, in the position to work FOR minorities not to
condone GENOCIDE on minorities.  His email address is in the headers of his
response to me.  Please help me on this issue.

Thanks,

Donna

==

Date: Tue, 22 Feb 2000 09:40:00 -0500
From: Tom_Daschle@daschle.senate.gov (Tom Daschle)
Subject: Re: Fwd: New `Tuskegee-Like Experiment' Planned with Pneumoc
To: Metis111@aol.com

New `Tuskegee-Like Experiment' Planned with Pneumococcal Pneumonia Vaccine,
Reported by Classen Immunotherapies

BALTIMORE, Feb. 18 /PRNewswire/ -- The following was released today by Classen
Immunotherapies, Inc.:

 The FDA cleared yesterday a controversial new pneumococcal pneumonia vaccine
with questionable safety and a US government advisory panel is planning to
selectively target black children and Native American children for immunization.
 This plan is being criticized for making children of certain racial minorities
"human guinea pigs".  It is possible that 1% or more of the children who receive
the vaccine may develop insulin dependent diabetes or another autoimmune disease
from the vaccine.

This week the Center for Disease Control and Prevention's Advisory Committee on
Immunization Practices recommended that children under 2 receive the new
pneumococcal vaccine but that black and Native American children age 2-5 be
selectively targeted for immunization.  This policy has come under criticism
because the vaccine has never been properly tested for safety and the FDA has
been told by an expert that the vaccine is expected to cause an epidemic of
autoimmune disease.

The controversial vaccine is the conjugated 7-valent pneumococcal vaccine which
is really a combination of 7 different vaccines, each to a separate strain of
pneumococcal pneumonia bacteria.  The vaccine is similar in structure to the
already marketed hemophilus meningitis vaccine, a vaccine linked to large
epidemics of insulin dependent diabetes.

Dr. J. Bart Classen, an immunologist at Classen Immunotherapies, published data
in the British Medical Journal (BMJ 1999; 319:1133) supporting a causal
relationship between the hemophilus vaccine and the development of insulin
dependent diabetes.  The vaccine has been incriminated in causing over 58 cases
of insulin dependent diabetes per 100,000 children immunized in Finland.  Dr.
Classen told the FDA at a recent meeting that the 7 valent pneumococcal vaccine
may be 7 times as toxic as the hemophilus vaccine, possibly causing an estimated
400 to 700 children to develop insulin dependent diabetes/100,000 children
immunized.  These cases of diabetes may not occur until 3.5 to 10 years
following immunization.

"The government's plan to selectively target black and Native Americans is
likely to have the effect of genocide, 0.5% of children who receive this vaccine
may develop insulin dependent diabetes from the vaccine and diabetes is just one
of many life threatening autoimmune disease," states Classen.  "I believe the
vaccine clearly should not have been approved by the FDA because it does not
meet the criteria for approval based on US law."

Dr. Classen's research has been published in numerous journals and featured in
national news reports. For the latest information on the effects of vaccines on
insulin dependent diabetes and other autoimmune diseases visit the Vaccine
Safety Website (http://vaccines.net)

 Classen Immunotherapies, Inc.

6517 Montrose Avenue

Baltimore, MD  21212  U.S.A.

Tel: 410-377-4549

Fax: 410-377-8526

Classen@vaccines.net

http://vaccines.net

 SOURCE  Classen Immunotherapies, Inc.

CO:  Classen Immunotherapies, Inc.; FDA; Center for Disease Control and
Prevention

ST:  Maryland, District of Columbia

IN:  HEA

SU:  BLK

02/18/2000 18:39 EST http://www.prnewswire.com

===

Dear Friend,

Thank you for taking the time to contact me via the Internet.  While I am
pleased to respond to messages from my constituents in South Dakota, I regret I
cannot reply to each message from across the country.

For South Dakota residents, if you have not already included your mailing
address, please resend your original message with your mailing address
and phone number.  I look forward to responding to your concerns.

Again, thank you for taking the time to write.  Please feel free
to contact me in the future via my web page at http://daschle.senate.gov/
webform.html

                          Sincerely,

                          Tom Daschle
                          United States Senate

===

This letter is sent to government officials as well as friends.  WE CANNOT
let this happen.  Just another way to commit genocide on minorities.  Our
childrens lives and health is at stake here.  This issue requires immediate
attention from all people.

Donna

<+>=<+>
Information Pages: http://users.skynet.be/kola/index.htm
Online Petition: http://kola-hq.hypermart.net
Greeting Cards: http://users.skynet.be/kola/cards.htm
<+>=<+>
if you want to be removed from the KOLA
Email Newslist, just send us a message with
"unsub" in the subject or text body
<+>=<+>